IONS News and Press, Ionis Pharmaceuticals Inc. From 02/17/26

Webcast scheduled for Wednesday, February 25 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live webcast, previously scheduled for 11:30 a.m. E...

2026-02-16 03:52:58 ET This article is part of a series that provides an ongoing analysis of the changes made to Tweedy Browne’s 13F portfolio on a quarterly basis. It is based on Tweedy Browne’s regulatory 13F Form filed on 02/03/2026. Please visit our Tracking Twee...

Webcast scheduled for Wednesday, February 25 at 11:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results a...

2026-02-06 07:04:34 ET from Piper Sandler issued a price target of $87.00 for IONS on 2026-02-06 11:52:48. The adjusted price target was set to $87.00. At the time of the announcement, IONS was trading at $83.48. The overall price target consensus is at $87.36 with high ...

Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose regimen of nusinersen also slowed neurodegeneration more rapidly, as measured by neuro...

2026-01-21 09:17:01 ET More on Ionis Pharmaceuticals, Otsuka Holdings Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ionis Pharmac...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (donidalorsen) in the European Union (EU) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adu...

2026-01-20 11:09:44 ET This is my lucky 13th article on Ionis ( IONS ), following my 09/2025 article — "Ionis: Recent Approvals, Upcoming Catalysts To Spur Strong Upside (Rating Upgrade)". It has been thumbs up for Ionis since this last article as it has risen ~20%.... ...

2026-01-20 05:45:00 ET With 2026 underway, there is a lot for investors to navigate. TD Cowen has come out with its Best Ideas 2026 report, and among the key takeaways - this year is likely going to look a lot like last year. Lisa Thomas, Managing Director, Deputy Head of Global Researc...

2026-01-19 07:35:54 ET Cathie Wood’s ARK Invest ( ARKK ) deepened investment in AI chipmakers, gene-editing companies, and autonomous-driving developers while continuing to trim positions in Tesla ( TSLA ) and several mature tech companies and life...